For UK pharmaceutical and life sciences leaders
You have real-world patient data sitting unused while competitors shape prescribing decisions
NHS commissioners and clinicians increasingly weight post-marketing evidence above trial data when making formulary and prescribing choices. If your team cannot translate that data into credible marketing assets, the influence goes elsewhere.
Two minutes. Solva follows up with specific real-world evidence activation options.
- Difficulty in demonstrating product value to NHS commissioners and private payers
- Slower than expected formulary inclusion or market uptake
- Marketing messages that fail to resonate with healthcare professionals
- Inability to effectively counter competitor claims based on RWE
- Inefficient resource allocation within medical affairs and market access teams
- Increased burden on internal teams to generate and synthesize RWE without clear strategy
- Loss of market share and revenue for pharmaceutical companies
- Increased costs associated with prolonged market access processes
- Delayed patient access to innovative treatments
- Suboptimal treatment pathways due to lack of real-world effectiveness data
- Perception of being slow to innovate or adopt modern evidence generation methods
- Reduced trust from healthcare professionals and commissioners
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
Real-world evidence (RWE) from post-marketing surveillance and patient registries is increasingly valued by NHS commissioners and HCPs as more relevant than clinical trial data. Pharma companies that fail to publish and communicate RWE miss a significant opportunity to reinforce prescribing confidence and support formulary inclusion.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.